Good Start Genetics

goodstartgenetics.com

Good Start Genetics is dedicated to helping grow healthy families through its best-in-class genetics offerings. Using advanced clinical sequencing, proprietary methods and information tailored to the individual, the Company's suite of offerings arms clinicians and patients with insightful and actionable information to promote successful pregnancies and help build healthy families. The Company’s product portfolio, including GeneVu, EmbryVu and VeriYou, encompasses a multifaceted approach to genetic testing, featuring solutions for both preimplantation and carrier screening, while offering comprehensive and flexible testing options helping a wider range of couples find their paths to pregnancy at significantly lower costs. Good Start Genetics complements these offerings with world class customer care and genetic counseling to help families stay well-informed and be better prepared for tomorrow.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AXON NEUROSCIENCE, A CLINICAL-STAGE BIOTECH COMPANY TO LAUNCH WORLD'S FIRST CROWDFUNDED VACCINE AGAINST COVID-19

COVIDAX | September 19, 2020

news image

AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1. With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine agains...

Read More

NOVAVAX SELECTS AGC BIOLOGICS TO MANUFACTURE MATRIX-M™ ADJUVANT FOR NOVEL COVID-19 VACCINE

AGC Biologics | June 03, 2020

news image

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhan...

Read More

Industrial Impact

MERAKRIS AND DEPT. OF VETERANS AFFAIRS SIGN CRADA AGREEMENT – CLINICAL TRIAL FOR DERMACYTE® WOUND CARE PRODUCT TO BEGIN SOON

Merakris Therapeutics | February 09, 2022

news image

Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to test its investigational drug product, Dermacyte® Amniotic Wound Care Liquid. The VA plans to enroll patients, ages 18-75, in a two-part Phase II clinical study to evaluate Merakris’ first in class subcutaneous – or below the skin – injectable wound healing therapy. The study is designe...

Read More

Cell and Gene Therapy

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

news image

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More
news image

AXON NEUROSCIENCE, A CLINICAL-STAGE BIOTECH COMPANY TO LAUNCH WORLD'S FIRST CROWDFUNDED VACCINE AGAINST COVID-19

COVIDAX | September 19, 2020

AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 – ACvac1. With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine agains...

Read More
news image

NOVAVAX SELECTS AGC BIOLOGICS TO MANUFACTURE MATRIX-M™ ADJUVANT FOR NOVEL COVID-19 VACCINE

AGC Biologics | June 03, 2020

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhan...

Read More
news image

Industrial Impact

MERAKRIS AND DEPT. OF VETERANS AFFAIRS SIGN CRADA AGREEMENT – CLINICAL TRIAL FOR DERMACYTE® WOUND CARE PRODUCT TO BEGIN SOON

Merakris Therapeutics | February 09, 2022

Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to test its investigational drug product, Dermacyte® Amniotic Wound Care Liquid. The VA plans to enroll patients, ages 18-75, in a two-part Phase II clinical study to evaluate Merakris’ first in class subcutaneous – or below the skin – injectable wound healing therapy. The study is designe...

Read More
news image

Cell and Gene Therapy

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us